These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31234141)

  • 1. Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans.
    Thiele S; Hannemann A; Winzer M; Baschant U; Weidner H; Nauck M; Thakker RV; Bornhäuser M; Hofbauer LC; Rauner M
    Endocr Connect; 2019 Jul; 8(7):923-934. PubMed ID: 31234141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt Inhibitors and Bone Turnover Markers in Patients With Polymyalgia Rheumatica and Acute Effects of Glucocorticoid Treatment.
    Fassio A; Adami G; Idolazzi L; Giollo A; Viapiana O; Vantaggiato E; Benini C; Rossini M; Dejaco C; Gatti D
    Front Med (Lausanne); 2020; 7():551. PubMed ID: 33015101
    [No Abstract]   [Full Text] [Related]  

  • 3. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
    Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
    Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF-2 targets sclerostin in bone and myostatin in skeletal muscle to mitigate the deleterious effects of glucocorticoid on musculoskeletal degradation.
    Adhikary S; Choudhary D; Tripathi AK; Karvande A; Ahmad N; Kothari P; Trivedi R
    Life Sci; 2019 Jul; 229():261-276. PubMed ID: 31082400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
    Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
    Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of endogenous hypercortisolism on bone mRNA and microRNA expression in humans.
    Belaya ZE; Grebennikova TA; Melnichenko GA; Nikitin AG; Solodovnikov AG; Brovkina OI; Grigoriev AU; Rozhinskaya LY; Dedov II
    Osteoporos Int; 2018 Jan; 29(1):211-221. PubMed ID: 28980049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
    Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
    Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
    Pietrzyk B; Smertka M; Chudek J
    Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dicer ablation in osteoblasts by Runx2 driven cre-loxP recombination affects bone integrity, but not glucocorticoid-induced suppression of bone formation.
    Liu P; Baumgart M; Groth M; Wittmann J; Jäck HM; Platzer M; Tuckermann JP; Baschant U
    Sci Rep; 2016 Aug; 6():32112. PubMed ID: 27554624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1.
    Tsourdi E; Rijntjes E; Köhrle J; Hofbauer LC; Rauner M
    Endocrinology; 2015 Oct; 156(10):3517-27. PubMed ID: 26218891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Glucocorticoid Receptor Actions in Bone Homeostasis and Bone Diseases.
    Lee S; Krüger BT; Ignatius A; Tuckermann J
    Front Endocrinol (Lausanne); 2021; 12():815386. PubMed ID: 35082759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of WNT16 Does Not Prevent Cortical Bone Loss Due to Glucocorticoid Treatment in Mice.
    Alam I; Oakes DK; Reilly AM; Billingsley C; Sbeta S; Gerard-O'Riley RL; Acton D; Sato A; Bellido T; Econs MJ
    JBMR Plus; 2019 Apr; 3(4):e10084. PubMed ID: 31044183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
    Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
    Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone ultrasonography in glucocorticoid-induced osteoporosis.
    Cepollaro C; Gonnelli S; Rottoli P; Montagnani A; Caffarelli C; Bruni D; Nikiforakis N; Fossi A; Rossi S; Nuti R
    Osteoporos Int; 2005 Jul; 16(7):743-8. PubMed ID: 15459804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strain-specific differences in the development of bone loss and incidence of osteonecrosis following glucocorticoid treatment in two different mouse strains.
    Shidara K; Mohan G; Evan Lay YA; Jepsen KJ; Yao W; Lane NE
    J Orthop Translat; 2019 Jan; 16():91-101. PubMed ID: 30723686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling.
    Wu Y; Xu SY; Liu SY; Xu L; Deng SY; He YB; Xian SC; Liu YH; Ni GX
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):470-478. PubMed ID: 28239825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Sclerostin Level Among Egyptian Rheumatoid Arthritis Patients: Relation to Disease Activity, Bone Mineral Density and Radiological Grading.
    Mehaney DA; Eissa M; Anwar S; Fakhr El-Din S
    Acta Reumatol Port; 2015; 40(3):268-74. PubMed ID: 26535777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WNT16 overexpression partly protects against glucocorticoid-induced bone loss.
    Ohlsson C; Nilsson KH; Henning P; Wu J; Gustafsson KL; Poutanen M; Lerner UH; Movérare-Skrtic S
    Am J Physiol Endocrinol Metab; 2018 Jun; 314(6):E597-E604. PubMed ID: 29406783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis.
    Koenen M; Culemann S; Vettorazzi S; Caratti G; Frappart L; Baum W; Krönke G; Baschant U; Tuckermann JP
    Ann Rheum Dis; 2018 Nov; 77(11):1610-1618. PubMed ID: 29997111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.